2018
DOI: 10.1080/21691401.2018.1481863
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The epidermal growth factor receptor (EGFR) is a cell surface receptor belonging to erythroblastic leukemia viral oncogene homologue (ErbB) family of tyrosine kinase. It plays critical role in the regulation of cell proliferation, survival and differentiation. The EGFR receptor is crucial in a variety of tumor development due to unlikely triggered by receptor overexpression, chromosomal mutation and or ligand-dependent receptor dimerization. The EGFR inhibition established a major therapeutic target in cancer … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
13
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 44 publications
(13 citation statements)
references
References 48 publications
0
13
0
Order By: Relevance
“…The current study aimed to design, optimize, and develop α-MNG-PLGA NPs and analyze the skin permeation and retention of the drug from nanocarriers within the distinguished layer of animal skin [ 23 , 24 ]. The formulation was tested in a melanoma cell line for its anticancer and antioxidant properties.…”
Section: Introductionmentioning
confidence: 99%
“…The current study aimed to design, optimize, and develop α-MNG-PLGA NPs and analyze the skin permeation and retention of the drug from nanocarriers within the distinguished layer of animal skin [ 23 , 24 ]. The formulation was tested in a melanoma cell line for its anticancer and antioxidant properties.…”
Section: Introductionmentioning
confidence: 99%
“…19 Briefly, the passively targeted NPs release substantial part of therapeutics to tumor tissue and get accumulated owing to the EPR effect which mediated passive-targeting approach. 20,21 To avail this technology, nanomedicine-based strategies are the most prominent of therapeutic approaches in cancer treatment. 22,23 Natural products have been proved to play a key role in suppressing the cancer proliferation via different mechanisms in recent years.…”
Section: Introductionmentioning
confidence: 99%
“…HER1 and HER2 are clinically validated targets in several cancers, such as squamous cell carcinoma of the head and neck [23], colorectal [24], breast [25], gastric [26], brain [27], and non-small cell lung cancers [28]. And growing evidence suggests that HER3 will prove to be a clinically relevant target as well [8].…”
Section: Discussionmentioning
confidence: 99%